JP2015530971A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530971A5
JP2015530971A5 JP2015520685A JP2015520685A JP2015530971A5 JP 2015530971 A5 JP2015530971 A5 JP 2015530971A5 JP 2015520685 A JP2015520685 A JP 2015520685A JP 2015520685 A JP2015520685 A JP 2015520685A JP 2015530971 A5 JP2015530971 A5 JP 2015530971A5
Authority
JP
Japan
Prior art keywords
seq
tau
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520685A
Other languages
English (en)
Japanese (ja)
Other versions
JP6345655B2 (ja
JP2015530971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/049333 external-priority patent/WO2014008404A1/en
Publication of JP2015530971A publication Critical patent/JP2015530971A/ja
Publication of JP2015530971A5 publication Critical patent/JP2015530971A5/ja
Application granted granted Critical
Publication of JP6345655B2 publication Critical patent/JP6345655B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520685A 2012-07-03 2013-07-03 タウに対する抗体 Expired - Fee Related JP6345655B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261667515P 2012-07-03 2012-07-03
US61/667,515 2012-07-03
US201261694989P 2012-08-30 2012-08-30
US61/694,989 2012-08-30
PCT/US2013/049333 WO2014008404A1 (en) 2012-07-03 2013-07-03 Antibodies to tau

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018098889A Division JP2018184398A (ja) 2012-07-03 2018-05-23 タウに対する抗体

Publications (3)

Publication Number Publication Date
JP2015530971A JP2015530971A (ja) 2015-10-29
JP2015530971A5 true JP2015530971A5 (enExample) 2016-08-18
JP6345655B2 JP6345655B2 (ja) 2018-06-20

Family

ID=49882495

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015520685A Expired - Fee Related JP6345655B2 (ja) 2012-07-03 2013-07-03 タウに対する抗体
JP2018098889A Pending JP2018184398A (ja) 2012-07-03 2018-05-23 タウに対する抗体
JP2020070416A Pending JP2020125310A (ja) 2012-07-03 2020-04-09 タウに対する抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018098889A Pending JP2018184398A (ja) 2012-07-03 2018-05-23 タウに対する抗体
JP2020070416A Pending JP2020125310A (ja) 2012-07-03 2020-04-09 タウに対する抗体

Country Status (17)

Country Link
US (2) US9834596B2 (enExample)
EP (2) EP2870176A4 (enExample)
JP (3) JP6345655B2 (enExample)
KR (3) KR102494798B1 (enExample)
CN (2) CN104781278B (enExample)
AU (3) AU2013286680B2 (enExample)
BR (1) BR112014033116B1 (enExample)
CA (1) CA2877397A1 (enExample)
HK (1) HK1209768A1 (enExample)
IL (3) IL236409B (enExample)
IN (1) IN2015KN00007A (enExample)
MX (2) MX359555B (enExample)
MY (1) MY171473A (enExample)
NZ (2) NZ703423A (enExample)
RU (2) RU2018132044A (enExample)
SG (3) SG11201408626YA (enExample)
WO (1) WO2014008404A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013286680B2 (en) 2012-07-03 2018-07-05 Washington University Antibodies to tau
ES2775192T3 (es) 2012-08-16 2020-07-24 Ipierian Inc Procedimientos de tratamiento de una tauopatía
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
KR102313513B1 (ko) * 2013-03-13 2021-10-15 프로테나 바이오사이언시즈 리미티드 Tau 면역치료제
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EP3160999B1 (en) * 2014-06-26 2018-11-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
EP3760235A1 (en) 2014-09-30 2021-01-06 Washington University Tau kinetic measurements
MA41451A (fr) * 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
CA2986942C (en) 2015-06-05 2025-07-22 Ac Immune Sa Anti-tau antibodies and their methods of use
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PT3334761T (pt) * 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
CN109580954B (zh) * 2015-09-16 2022-03-22 北京九强生物技术股份有限公司 一种人肌钙蛋白i的超敏定量测定试剂盒及其检测方法
JP7170316B2 (ja) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
JP7194985B2 (ja) 2016-05-02 2022-12-23 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
WO2017191560A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
PE20190227A1 (es) 2016-07-12 2019-02-13 H Lundbeck As Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
EP3541836A1 (en) 2016-11-15 2019-09-25 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
KR20230146126A (ko) 2016-12-07 2023-10-18 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
CN106749658B (zh) * 2016-12-15 2019-11-12 北京师范大学 抑制Tau蛋白聚集的抗体型分子伴侣
US11325968B2 (en) 2016-12-16 2022-05-10 H. Lundbeck A/S Alpha-synuclein antibodies
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
WO2018165015A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
TWI809562B (zh) * 2017-10-16 2023-07-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
CN112004827A (zh) * 2018-03-23 2020-11-27 艾伯维德国有限责任两合公司 稳定的水性抗tau抗体调配物
WO2019207164A1 (en) * 2018-04-27 2019-10-31 Ecole Polytechnique Federale De Lausanne (Epfl) A method for preparing phfs-like tau aggregates
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
CN109613242A (zh) * 2018-11-01 2019-04-12 深圳天辰医疗科技有限公司 一种肌酸激酶同工酶检测试剂盒及其制备方法
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
US11845931B2 (en) * 2019-03-18 2023-12-19 Regeneron Pharmaceuticals, Inc. CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
CN113711046B (zh) * 2019-03-18 2023-08-29 瑞泽恩制药公司 用于揭示与Tau聚集相关的基因脆弱性的CRISPR/Cas脱落筛选平台
CN110055280A (zh) * 2019-03-19 2019-07-26 深圳大学 一种稳定表达mCherry-tau的细胞系及其构建方法与应用
MX2022000603A (es) * 2019-07-15 2022-05-20 Adel Inc Anticuerpo anti-tau y uso del mismo.
AU2020331020A1 (en) * 2019-08-13 2022-03-03 Washington University Methods to detect MTBR tau isoforms and use thereof
EP4041864A1 (en) 2019-10-09 2022-08-17 Bluerock Therapeutics LP Cells with sustained transgene expression
CA3159964A1 (en) * 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
EP4241088A1 (en) * 2020-11-09 2023-09-13 Meso Scale Technologies, LLC Methods and kits for detecting tau
US20240101654A1 (en) 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies
AU2022246275A1 (en) 2021-03-26 2023-11-09 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof
AU2022242135A1 (en) 2021-03-26 2023-11-09 Janssen Biotech, Inc. Anti-tau antibodies and uses thereof
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
AU2023329330A1 (en) * 2022-08-23 2025-02-06 Washington University Anti-tau mtbr antibodies and methods to detect cleaved fragments of tau and uses thereof
WO2025018933A1 (en) * 2023-07-20 2025-01-23 Montoliu Gaya Laia P-tau immunoassay

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK546988A (da) 1987-10-02 1989-04-03 Du Pont Immunobestemmelse og reagenssaet til anvendesle herved
AU2414092A (en) 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
CA2121599C (en) 1991-10-25 2007-04-10 Marc Mercken Monoclonal antibodies directed against the microtubule-associated protein tau
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
JPH10506381A (ja) 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
RU2238947C2 (ru) * 1998-07-14 2004-10-27 Янссен Фармацевтика Н.В. Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты)
EP1112500B1 (en) 1998-09-08 2004-09-22 Innogenetics N.V. Tau as a marker for early cns damage
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
EP3960855A1 (en) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
PT2371392E (pt) 2002-05-02 2015-10-07 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
JP4308760B2 (ja) 2002-07-12 2009-08-05 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング トランケートｔａｕタンパク質
AU2003257850A1 (en) 2002-08-14 2004-03-03 Mitsubishi Kagaku Iatron, Inc. ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005080986A1 (en) 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2006088281A1 (en) 2005-02-19 2006-08-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
EP1940442A4 (en) 2005-08-04 2009-08-19 Einstein Coll Med Phosphorylation of tau by abl
ES2321996B1 (es) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
HUE024506T2 (en) 2008-04-24 2016-01-28 Bristol Myers Squibb Co The use of epothilone D for the treatment of tau-associated diseases such as Alzheimer's disease
CN101307108B (zh) 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
ES2645692T3 (es) * 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
WO2010096751A1 (en) 2009-02-23 2010-08-26 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
CA3120504A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2011013034A1 (en) * 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
JP6124591B2 (ja) 2009-08-28 2017-05-10 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
ES2687469T3 (es) * 2009-09-14 2018-10-25 Banyan Biomarkers, Inc. Marcadores autoanticuerpos para el diagnóstico de traumatismo craneoencefálico
WO2011045166A1 (en) 2009-09-24 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2011109112A2 (en) 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
ES2548686T3 (es) * 2010-10-07 2015-10-20 Ac Immune S.A. Anticuerpos que reconocen fosfo-Tau
AU2011315181B2 (en) * 2010-10-11 2016-07-28 Biogen International Neuroscience Gmbh Human anti-tau antibodies
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
WO2012149365A2 (en) 2011-04-27 2012-11-01 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
WO2012162179A1 (en) 2011-05-20 2012-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013012811A2 (en) 2011-07-19 2013-01-24 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
SMT201800109T1 (it) 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
BR112014008202B1 (pt) 2011-10-07 2022-01-04 Ac Immune S.A. Anticorpo, polinucleotídeo, composição farmacêutica, usos de um anticorpo, método in vitro, método de detecção da formação de um complexo imunológico, método de detecção post­mortem de multimêros do fosfo-tau, kits de teste, linhagem celular isolada e método de detecção de multimêros de fosfo-tau
US20140294724A1 (en) 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
PT2794654T (pt) 2011-12-20 2019-09-10 Janssen Biotech Inc Anticorpos anti-phf-tau e suas utilizações
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
HRP20192267T1 (hr) 2012-05-31 2020-03-20 Osaka City University Terapeutski agens ili profilaktički agens za demenciju
AU2013286680B2 (en) 2012-07-03 2018-07-05 Washington University Antibodies to tau
ES2775192T3 (es) 2012-08-16 2020-07-24 Ipierian Inc Procedimientos de tratamiento de una tauopatía
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP2887955B1 (en) 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
AU2013328881B2 (en) 2012-10-12 2018-03-15 Arizona Board Of Regents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9910048B2 (en) 2012-12-03 2018-03-06 Washington University Method for detection of aggregates in biological samples
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
US9598484B2 (en) 2012-12-21 2017-03-21 Biogen Ma Inc. Human anti-tau antibodies
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
KR102313513B1 (ko) 2013-03-13 2021-10-15 프로테나 바이오사이언시즈 리미티드 Tau 면역치료제
WO2014159244A2 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
CA2902910A1 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
WO2014152157A2 (en) 2013-03-15 2014-09-25 Bethisrael Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體

Similar Documents

Publication Publication Date Title
JP2015530971A5 (enExample)
RU2015103228A (ru) Антитела против тау
JP2014526898A5 (enExample)
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
RU2016100892A (ru) Антитела против tweakr и их применение
JP2013500940A5 (enExample)
JP2010526028A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
JP2013538057A5 (enExample)
JP2017535257A5 (enExample)
JP2015535828A5 (enExample)
JP2013500941A5 (enExample)
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
JP2021500916A5 (enExample)
JP2014511179A5 (enExample)
JP2016508496A5 (enExample)
JP2013506428A5 (enExample)
HRP20230844T1 (hr) Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe
RU2017145653A (ru) Средства, пути применения и способы лечения синуклеопатии
JP2014512809A5 (enExample)
JP2015531768A5 (enExample)
JP2016501881A (ja) 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
JP2016509585A5 (enExample)